Most employers in the United States are not required by federal law to drug test their workers. Nuclear power is one of the few industries where that is not true. Under the Nuclear Regulatory Commission's fitness for duty rule, codified at 10 CFR Part 26, every licensee operating a commercial nuclear power reactor must run a drug and alcohol testing program for people who work inside the plant's protected areas. This is a federal licensing condition, not a voluntary policy choice, and it applies whether the plant sits in a state that has legalized recreational marijuana or not.
This post walks through what Part 26 requires: who it covers, the five categories of testing, the drug and alcohol panel, how licensee testing facilities and HHS certified laboratories divide the work, the Medical Review Officer's role, and the sanctions a confirmed violation triggers. It also compares Part 26 briefly with the Department of Transportation's testing rule. American Screening Corporation supplies collection cups, dip devices and oral fluid screens used in regulated testing programs, but the licensee's own fitness for duty program, not the device vendor, determines which specific devices, cutoffs and laboratories a given plant uses.
Who the rule covers
Part 26 applies to licensees authorized to operate a nuclear power reactor, and to certain licensees who possess, use or transport large quantities of strategic special nuclear material. The obligation attaches to anyone granted unescorted access to a reactor's protected area who performs duties the rule treats as significant to public health, safety or security: people who operate or direct safety significant systems, health physics or chemistry staff on the emergency response team, fire brigade members, maintenance personnel on safety significant structures and components, and armed security officers, alarm station operators and watchmen. Contractors and vendors performing fitness for duty program functions for a licensee are also covered.
The regulation's performance objectives require licensees to provide reasonable assurance that covered individuals are trustworthy and reliable, are not impaired by any substance while on duty, and that the workplace is free from the presence and effects of illegal drugs and alcohol. Those objectives are why the rule reaches further than a typical workplace drug policy, since it is written around public safety and security at a reactor, not general productivity or liability concerns.
Five categories of required testing
Part 26 does not leave testing frequency or triggers to a licensee's discretion. The rule sets out specific categories that a compliant program must include:
| Testing category | When it applies |
|---|---|
| Pre access (pre employment) | Before a person is granted unescorted access or authorization, generally within a short window before access is granted |
| Random | Unannounced, spread across the year on an unpredictable schedule, including weekends, backshifts and holidays |
| For cause | Triggered by observed behavior or a physical condition creating reasonable suspicion of substance use or impairment |
| Post event | Required after specified plant events, without delaying any necessary emergency medical treatment |
| Follow up | Required after a confirmed violation, as part of monitoring an individual's return to authorized status |
Random testing carries a specific numeric requirement that sets Part 26 apart from most voluntary programs: the number of random tests performed in a year must equal at least 50 percent of the population subject to the program, administered on at least a nominal weekly basis so no one can predict when a collection will occur. Every covered individual must have an equal chance of being selected each time, and someone who just completed a random test remains immediately eligible for another unannounced one.
What the Part 26 panel tests for
The Part 26 panel is built on the same core drug classes used in the federal workplace drug testing program that the Department of Health and Human Services administers for other agencies, but it expands two of those classes. At minimum, licensees must test for marijuana metabolite, cocaine metabolite, an expanded opioid group (codeine, morphine, 6 acetylmorphine, hydrocodone, hydromorphone, oxycodone and oxymorphone), an expanded amphetamine group (amphetamine, methamphetamine, MDMA and MDA), phencyclidine, and alcohol. SAMHSA's workplace page describes the federal Mandatory Guidelines that the standard five panel federal test builds from, useful context for seeing how Part 26 both overlaps with and exceeds that baseline.
HHS certified laboratories apply specific cutoff concentrations when they run the initial test on a urine specimen to decide whether it is negative or positive. The table below lists the initial test cutoffs set out in the regulation.
| Drug or drug metabolite | Initial test cutoff (ng/mL) |
|---|---|
| Marijuana metabolite | 50 |
| Cocaine metabolite | 150 |
| Codeine / morphine | 2,000 |
| Hydrocodone / hydromorphone | 300 |
| Oxycodone / oxymorphone | 100 |
| 6 acetylmorphine (6-AM) | 10 |
| Phencyclidine (PCP) | 25 |
| Amphetamine / methamphetamine | 500 |
| MDMA / MDA | 500 |
A positive initial screen is not a confirmed violation. It goes on to confirmatory testing at the HHS certified laboratory using a more specific method, and confirmatory cutoffs differ from, and are generally lower than, the initial screening cutoffs shown above. A licensee may adopt a stricter cutoff than the regulation sets, but may not test for substances outside this list unless a qualified forensic toxicologist certifies the added assay and cutoff, or the licensee is testing for a suspected drug of abuse during for cause, post event or follow up testing under the rule's separate provision for that situation.
Licensee testing facilities and HHS certified laboratories
Part 26 programs typically run through two kinds of testing sites, each with a distinct and limited role. A licensee testing facility is an on site facility the licensee or its contractor operates to perform validity screening and initial drug testing of urine specimens. Licensee testing facility personnel inspect incoming specimens, run the initial screening tests, and keep the chain of custody intact before a specimen clears as negative or moves forward. Because those tests are only an initial screen, the rule sharply limits what a licensee can do with that result alone: outside of marijuana and cocaine metabolite results handled under strict conditions, including a documented confirmation rate requirement and no loss of pay while a result is pending, a licensee generally cannot take administrative action based solely on an initial, unconfirmed result.
Confirmatory testing, and testing beyond what a licensee testing facility screens, is performed by a laboratory certified by HHS under the same certification program that supports other federal drug testing programs. That laboratory performs the confirmatory analysis, handles split specimen testing when requested, and reports results to the Medical Review Officer rather than directly to plant management.
The Medical Review Officer's role
No positive result becomes a confirmed violation without review by a Medical Review Officer, a licensed physician trained to interpret a donor's drug and specimen validity results together with the donor's medical history. Under 10 CFR 26.185, the MRO must review every positive, adulterated, substituted, dilute or invalid result from the HHS certified laboratory before any result reaches the licensee, contacting the donor to discuss it before the result can be treated as confirmed. A current prescription or other legitimate medical explanation can account for some positive results, exactly what this review step exists to catch before any sanction applies. Alcohol testing works differently: a positive confirmatory result from an evidential breath testing device is treated as confirmed without a parallel MRO review step.
Sanctions for confirmed violations
Part 26 sets minimum sanctions, and licensees may apply stricter consequences on top of these floors. Any attempt to subvert testing, including refusing to provide a specimen or submitting a substituted or adulterated specimen, results in immediate unfavorable termination and permanent denial of future authorization. Confirmed sale, use or possession of illegal drugs, or alcohol use, within a protected area or while performing covered duties also carries immediate termination and a minimum five year denial. A first confirmed positive that does not involve on site use triggers, at minimum, unfavorable termination for at least fourteen days, and any later confirmed positive carries a minimum five year denial. An individual who already served a five year denial and violates the policy again faces permanent denial. Misuse of a legitimately prescribed or over the counter drug is handled differently unless the MRO determines the misuse amounts to substance abuse, in which case sanctions still must be sufficient to deter it.
How this compares with DOT testing
Employers used to Department of Transportation drug and alcohol testing sometimes assume nuclear fitness for duty testing works the same way. The two programs share a common ancestor in the federal workplace testing framework, but separate regulations and separate agencies stand behind each one. DOT testing for safety sensitive transportation employees is governed by 49 CFR Part 40, administered through each transportation mode's own agency, with panel and random testing percentages set and adjusted by those agencies rather than fixed at fifty percent by rule the way Part 26's random rate is. Part 26 is also broader than the baseline federal five panel test, since it folds in expanded opioid and amphetamine groups and layers on nuclear specific elements like behavioral observation, access authorization and, for many licensees, fatigue management. A nuclear licensee is not relieved of its Part 26 obligations by also running a DOT program for employees who drive commercial vehicles; the two programs apply side by side for anyone covered by both.
What this means for program design
Because Part 26 is enforced through NRC licensing rather than left to an employer's own policy, a licensee's fitness for duty program has to be built around the rule's specific definitions, not a generic drug testing template. That affects how a licensee testing facility documents chain of custody, which collection devices meet the rule's specimen integrity requirements, and how random selection proves it meets the equal probability and unpredictability standards the rule expects. American Screening Corporation manufactures collection cups, dip cards and oral fluid devices used across regulated testing programs, and contracted collection sites can review ordering options at the wholesale portal or browse drug test cups for standard volume. The licensee's own program and its HHS laboratory relationship still govern which devices and procedures are acceptable for Part 26 compliance at a given site.
Programs outside the nuclear sector that want to understand how a broader fitness for duty concept differs from a basic drug test may find it useful to read about impairment testing versus drug testing. For a closer look at how physician review works across regulated programs generally, see the Medical Review Officer process.
Frequently asked questions
Does federal law require drug testing at nuclear power plants?
Yes. The Nuclear Regulatory Commission's fitness for duty rule at 10 CFR Part 26 requires licensees that operate commercial nuclear power reactors to run a drug and alcohol testing program for individuals with unescorted access who perform safety or security significant duties. This is one of the few sectors, along with Department of Transportation covered positions, where federal regulation mandates testing rather than leaving it to employer discretion.
Who at a nuclear plant is actually subject to Part 26 testing?
The rule covers people granted unescorted access to a reactor's protected area who operate or direct safety significant systems, serve on the emergency response team or fire brigade, perform maintenance on safety significant structures and components, or work as armed security personnel, alarm station operators or watchmen. Contractors and vendors performing fitness for duty functions for a licensee are also covered.
What drugs does the Part 26 panel screen for?
At minimum, the panel covers marijuana metabolite, cocaine metabolite, an expanded opioid group including codeine, morphine, 6 acetylmorphine, hydrocodone, hydromorphone, oxycodone and oxymorphone, an expanded amphetamine group including amphetamine, methamphetamine, MDMA and MDA, phencyclidine, and alcohol. Licensees may add other scheduled drugs with proper forensic toxicologist certification of the assay and cutoff.
How often are nuclear plant workers randomly tested?
The rule requires that the number of random tests conducted each year equal at least fifty percent of the population subject to the program, administered at a minimum nominal weekly frequency on an unpredictable schedule, so individuals cannot anticipate when they will be selected.
What happens after a confirmed positive test under Part 26?
A confirmed positive, reviewed by a Medical Review Officer, triggers minimum sanctions set by the rule: a first confirmed positive generally means unfavorable termination for at least fourteen days, a later confirmed positive carries a minimum five year denial, and subverting testing or confirmed on site drug or alcohol activity carries stricter consequences, including permanent denial in some cases.
Is NRC Part 26 testing the same as DOT drug testing?
No. They are separate federal regulations administered by different agencies. DOT testing for safety sensitive transportation employees runs under 49 CFR Part 40, with panel and random testing rates set by each transportation mode's agency. Part 26 is specific to NRC licensees, uses a broader drug panel, and sets its random testing rate directly in the rule rather than through periodic agency adjustment. An individual subject to both programs must comply with each one independently.
This article is general information about a federal regulation and is not legal advice. Licensees should work with qualified counsel and their HHS certified laboratory and Medical Review Officer to confirm current program requirements.
